Translational research in pancreatic cancer: KRAS and beyond

Pancreas

Volumn 43, Issue 1, 2014, Pages 150-152

  Boeck, Stefan ^a   Ormanns, Steffen ^b   Haas, Michael ^a   Bächmann, Sibylle ^a   Laubender, Rüdiger P ^b   Siveke, Jens T ^c   Jung, Andreas ^b   Kirchner, Thomas ^b   Heinemann, Volker ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ERLOTINIB; GEMCITABINE; K RAS PROTEIN; SMAD4 PROTEIN;

ADENOCARCINOMA; ADJUVANT THERAPY; ADVANCED CANCER; BILE DUCT CARCINOMA; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL PRACTICE; DRUG EFFICACY; DUODENUM CARCINOMA; GENE MUTATION; HUMAN; LETTER; METASTASIS; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYSTEMIC THERAPY; TRANSLATIONAL RESEARCH; WILD TYPE;

CARCINOMA, PANCREATIC DUCTAL; FEMALE; HUMANS; MALE; MUTATION; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, ERBB-2; SMAD4 PROTEIN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84891518096     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31829629f6     Document Type: Letter

References (14)

1. Shin SH, Kim SC, Hong SM, et al. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival. Pancreas. 2013;42(2):216-222.
2. Lee J, Jang KT, Ki CS, et al. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer. 2007; 109(8):1561-1569. (Pubitemid 46595692)
3. Chen H, Tu H, Meng ZQ, et al. K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer. Eur J Surg Oncol. 2010;36(7):657-662.
4. Ogura T, Yamao K, Hara K, et al. Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer. J Gastroenterol. 2013;48(5):640-646.
5. Kim ST, Lim do H, Jang KT, et al. Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy. Mol Cancer Ther. 2011;10(10):1993-1999.
6. Da Cunha Santos G, Dhani N, Tu D, et al. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3. Cancer. 2010;116(24):5599-5607.
7. Boeck S, Jung A, Laubender RP, et al. EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104. Br J Cancer. 2013; 108(2):469-476.
8. Oliveira-Cunha M, Hadfield KD, Siriwardena AK, et al. EGFR and KRAS mutational analysis and their correlation to survival in pancreatic and periampullary cancer. Pancreas. 2012;41(3):428-434.
9. Tempero MA, Klimstra D, Berlin J, et al. Changing the way we do business: recommendations to accelerate biomarker development in pancreatic cancer. Clin Cancer Res. 2013;19(3):538-540.
10. Crane CH, Varadhachary GR, Yordy JS, et al. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol. 2011;29(22):3037-3043.
11. Bachet JB, Maréchal R, Demetter P, et al. Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma. Ann Oncol. 2012;23(9):2327-2335.
12. Winter JM, Tang LH, Klimstra DS, et al. Failure patterns in resected pancreas adenocarcinoma: lack of predicted benefit to SMAD4 expression. Ann Surg. 2013;258(2):331-335.
13. Farrell JJ, Elsaleh H, Garcia M, et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology. 2009;136(1):187-195.
14. Poplin E,Wasan H, Rolfe L, et al. Randomized multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and a prospective evaluation of the of the association between tumor hENT1 expression and clinical outcome with gemcitabine treatment. J Clin Oncol. 2013;31 (suppl): abstract 4007.